Liprotamase - Alkira Therapeutics

Drug Profile

Liprotamase - Alkira Therapeutics

Alternative Names: ALTU-135; Liprotamase; LY-3031642; Sollpura; TheraCLEC™-Total; Trizytek™

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics
  • Developer Anthera Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics
  • Class Amylases; Carboxylic ester hydrolases; Pancreatic enzymes; Peptide hydrolases
  • Mechanism of Action Amylase replacements; Lipase replacements; Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Exocrine pancreatic insufficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Exocrine pancreatic insufficiency

Most Recent Events

  • 09 Nov 2017 Anthera Pharmaceuticals completes enrolment in the phase III RESULT trial in Exocrine pancreatic insufficiency (In children, In adolescents, In adults) in USA, Hungary, Israel, Lithuania, Poland, Spain and United Kingdom
  • 14 Aug 2017 The European Cystic Fibrosis Society Clinical Trial Network Executive Committee approves the phase III RESULT study in Exocrine pancreatic insufficiency due to cystic fibrosis
  • 28 Apr 2017 Phase-III clinical trials in Exocrine pancreatic insufficiency (In children, In adolescents, In adults, In the elderly) in USA, United Kingdom, Spain, Poland, Lithuania, Israel, Hungary (PO) (NCT03051490)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top